Research on Ocular and Intraocular Tumors
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (15 August 2023) | Viewed by 3957
Special Issue Editors
Interests: uveal melanoma; ocular lymphoma; radiosurgery
Special Issue Information
Dear Colleagues,
Eye tumors are associated with the threat of losing sight or the eye itself, and are often associated with considerable distress for the patients. Each year, 1 out of every 100,000 individuals will be affected by a primary tumor.
Tumors of the eye are classified as orbital or intraocular neoplasia. Orbital diseases include lymphoma and metastasis. Primary orbital tumors are rare, such as cconjunctival melanoma, and are often difficult to treat, with high rates of recurrence and metastasis.
The most common intraocular malignancies are metastases, mostly from breast, lung or gastrointestinal cancers; effective systemic therapy usually achieves good intraocular disease control.
Choroidal melanoma has the highest prevalence of all primary intraocular tumors. Primary disease control and eye preservation are achieved in most patients, because effective and complementary treatment strategies, ascertaining to local tumor control, exist. Classically, brachytherapy with iodine or ruthenium plaques, proton therapy, or radiosurgery with photons are commonly being employed. Metastatic spread, however, has remained challenging and therapeutic options remain limited, although important progress has been made with immunotherapies in recent years.
The current Special Issue of Cancers is set to highlight novel developments in translational medicine, organ-preserving therapies for intraocular tumors, and innovative strategies regarding how to most appropriately deal with metastatic disease.
Dr. Lothar Krause
Dr. Ilja Frank Ciernik
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ocular oncology
- choroidal melanoma
- choroidal metastasis
- retinoblastoma
- lymphoma
- conjunctival melanoma
- brachytherapy
- proton therapy
- radiosurgery
